コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 apeutic targets for diet-induced obesity and metabolic disorder.
2 robiotics to attenuate high-fat diet-related metabolic disorder.
3 ice an HFD for 16 wk to initiate HFD-induced metabolic disorder.
4 nd adoptive transfer of AT1-ILCs exacerbated metabolic disorder.
5 dities, including cardiovascular disease and metabolic disorder.
6 conditions, and the etiology of this common metabolic disorder.
7 heral nerves as a new therapeutic target for metabolic disorders.
8 the recent rise of allergic, autoimmune and metabolic disorders.
9 ephalopathy (CADASIL), and mitochondrial and metabolic disorders.
10 ributing to accelerated body weight gain and metabolic disorders.
11 tment of acute liver failure and liver-based metabolic disorders.
12 ns for developing personalized therapies for metabolic disorders.
13 in many cancers, cardiovascular disease, and metabolic disorders.
14 ating the link between arsenite exposure and metabolic disorders.
15 aging and pathological conditions, including metabolic disorders.
16 de a means of treating hepatic steatosis and metabolic disorders.
17 n protecting against HFD-induced obesity and metabolic disorders.
18 tential therapeutic target for mTORC1-driven metabolic disorders.
19 as a consideration in the treatment of liver metabolic disorders.
20 the onset and/or progression of major immune/metabolic disorders.
21 who may be at higher risk for cardiovascular/metabolic disorders.
22 on that contributes to bone dysregulation in metabolic disorders.
23 nalog, could be developed as a treatment for metabolic disorders.
24 and represents a possible new drug target in metabolic disorders.
25 arning and are implicated in glucose-related metabolic disorders.
26 r se causes leptin resistance and associated metabolic disorders.
27 cidate the effect of KHK inhibition on these metabolic disorders.
28 that central vascular impairments may cause metabolic disorders.
29 sing CRISPR/Cas9, as a new strategy to model metabolic disorders.
30 se the risk of fatty liver disease and other metabolic disorders.
31 ating obesity, diabetes and their associated metabolic disorders.
32 e promising agents for treating a variety of metabolic disorders.
33 cally relevant for the prevention of glucose metabolic disorders.
34 munity to pathogens/tumors and in autoimmune/metabolic disorders.
35 safety profiles in the treatment of complex metabolic disorders.
36 ptation to ER stress associated with chronic metabolic disorders.
37 in the aetiology of sleep, mental health and metabolic disorders.
38 t been fully investigated in obesity-related metabolic disorders.
39 promising approach for targeting cancer and metabolic disorders.
40 logical iron reduction on the development of metabolic disorders.
41 as a protective factor in obesity and other metabolic disorders.
42 esting potential target for the treatment of metabolic disorders.
43 eurodegenerative diseases are accompanied by metabolic disorders.
44 rimary cause of obesity and other eating and metabolic disorders.
45 n and oxidative stress in an animal model of metabolic disorders.
46 Its dysregulation causes diabetes and other metabolic disorders.
47 ight serve as a therapeutic target in common metabolic disorders.
48 ising target for therapeutic intervention in metabolic disorders.
49 hts into strategies to treat obesity-related metabolic disorders.
50 , non-alcoholic steatohepatitis, and related metabolic disorders.
51 4 in managing obesity and obesity-associated metabolic disorders.
52 e (NNMT), an enzyme implicated in cancer and metabolic disorders.
53 ts a therapeutic avenue for the treatment of metabolic disorders.
54 mproved therapeutic strategies for combating metabolic disorders.
55 ssociated with increased risk for immune and metabolic disorders.
56 ntergenerational inheritance of diet-induced metabolic disorders.
57 iabetes may lead to promising treatments for metabolic disorders.
58 d has the potential to treat obesity-related metabolic disorders.
59 contribute to muscle wasting associated with metabolic disorders.
60 and excessive storage is a feature of common metabolic disorders.
61 le similar to dysbiotic states described for metabolic disorders.
62 rone is associated with all "Western" cardio-metabolic disorders.
63 c and diagnostic targets for obesity-related metabolic disorders.
64 Indians are known to be at elevated risk for metabolic disorders.
65 se energy expenditure in obesity and related metabolic disorders.
66 cluster of cardiovascular (hypertension) and metabolic disorders.
67 -MCA may be a candidate for the treatment of metabolic disorders.
68 ives to combat the rising global epidemic of metabolic disorders.
69 be associated with chronic liver disease and metabolic disorders.
70 reat neuroinflammation, obesity, and related metabolic disorders.
71 rnutrition increases the risk of obesity and metabolic disorders.
72 ce their pathogenic role in inflammatory and metabolic disorders.
73 omic loci contributing to cardiovascular and metabolic disorders.
74 timately cell death that underlie nearly all metabolic disorders.
75 physiological transitions are known to cause metabolic disorders.
76 based treatments for obesity and its related metabolic disorders.
77 ut microbiome are important risk factors for metabolic disorders.
78 strategy against inflammation, dysbiosis and metabolic disorders.
79 e chronic supposedly noncommunicable, immune/metabolic disorders.
80 a, the association of the gut microbiome and metabolic disorders.
81 evented but also reversed obesity-associated metabolic disorders.
82 midotransferase, result in devastating human metabolic disorders.
83 es associated with diseases such as gout and metabolic disorders.
84 ediated by VDR that might trigger downstream metabolic disorders.
85 s an attractive therapeutic strategy against metabolic disorders.
86 nked mutations in the DHTKD1 gene to several metabolic disorders.
87 rs, neurodegeneration, cancer, diabetes, and metabolic disorders.
88 herapeutic possibilities for ACLY-associated metabolic disorders.
89 in the initiation and progression of several metabolic disorders.
90 a range of musculoskeletal complications and metabolic disorders.
91 o-legal and post mortem examination, with no metabolic disorders.
92 c flexibility is a dominant cause of several metabolic disorders.
93 ans in the prevention and early detection of metabolic disorders.
94 al disease, one of the most common inherited metabolic disorders.
95 een associated with increased risk of cardio-metabolic disorders.
96 ful for the treatment of obesity and related metabolic disorders.
97 lsivity is common in various psychiatric and metabolic disorders.
98 opoietic failure, cancer predisposition, and metabolic disorders.
99 ing the implications of arsenite exposure in metabolic disorders.
100 arget for the treatment of obesity and other metabolic disorders.
101 gulator of blood pressure has been linked to metabolic disorders.
102 ansgenerational passage of obesity and other metabolic disorders, 3) DNA methylation is involved in r
103 Maple syrup urine disease (MSUD) is a rare metabolic disorder, affecting the metabolism of branched
104 obesity (MO) programs offspring obesity and metabolic disorders, although the underlying mechanisms
105 ase and type 2 diabetes MELLITUS (T2DM) is a metabolic disorder, an increasing number of genetic epid
106 to increased adult adiposity, inflammation, metabolic disorder and dyslipidemia in offspring fed a s
107 y differences in REE between patients with a metabolic disorder and healthy participants can be expre
108 sis in renal fibroblasts is an intracellular metabolic disorder and is inherently coupled with inflam
110 ovide one of the first examples of ERT for a metabolic disorder and suggest that PEGylated CBS should
112 edicting the disease status of patients with metabolic disorders and also the tumor stages and progno
113 ulin resistance are among the most prevalent metabolic disorders and are tightly associated with obes
116 processing of IL1beta, contributing to many metabolic disorders and directing adipocytes to a more i
118 f human health against general inflammation, metabolic disorders and disturbances of the digestive sy
119 inhibition approaches for treating other PIP metabolic disorders and highlight the importance of modi
120 iagnosis in 15 out of 17 (88%) children with metabolic disorders and in 5 out of 28 (~18%) children w
121 y liver disease is one of the most prevalent metabolic disorders and it tightly associates with obesi
122 s), aging WT mice (20-22 months) had obvious metabolic disorders and loss of locomotor activity.
123 tribution of signaling pathways that lead to metabolic disorders and NE differentiation of prostate c
124 this coupling is associated with a number of metabolic disorders and neurodegenerative diseases inclu
126 the past few years, the association between metabolic disorders and periodontitis has been widely st
127 ciated with cardiovascular, psychiatric, and metabolic disorders and triglycerides and high-density l
129 pertensive disease, circulatory disease, and metabolic disorders) and 9 disease outcomes (gout, gouty
130 immunodeficiencies, haemoglobinopathies and metabolic disorders) and for the generation of chimeric
135 sociated with increased incidence of cancer, metabolic disorders, and affective problems in humans.
136 ion, autoimmune diseases, cardiovascular and metabolic disorders, and cancer reported in shift worker
140 shown effects in mouse models of obesity and metabolic disorders, and how these might be translated t
142 we postulated that AIF1L might contribute to metabolic disorders, and studied it using mouse models.
143 Hepatitis C virus (HCV) infection promotes metabolic disorders, and the severity of lipogenic disea
152 y is central to the development of these two metabolic disorders, as adipose tissue plays a pivotal r
153 l polycystic ovary syndrome (PCOS), a common metabolic disorder associated with excess circulating an
154 ch reduced with this technology, diminishing metabolic disorders associated with cooling and minimizi
155 ide a potential therapeutic means to control metabolic disorders associated with its dysregulated sec
156 mation) is characteristic of obesity-related metabolic disorders, associated with increased risk of d
157 This suggests the presence of an underlying metabolic disorder beyond fatty liver that may be causat
158 effects and mechanisms of PM2.5 exposure in metabolic disorders, but also revealed the pleotrophic a
159 Consumption of dietary fat contributes to metabolic disorders, but EEC adaptations to high fat fee
160 ith an increased risk of obesity and related metabolic disorders, but the role of sleep in long-term
161 ty and type 2 diabetes are the most frequent metabolic disorders, but their causes remain largely unc
162 of CB1 ameliorates Diet-Induced Obesity and metabolic disorder by modulating macrophage inflammatory
163 nd shows that susceptibility of offspring to metabolic disorder can likely be attributed to epigeneti
164 remendous opportunities for the treatment of metabolic disorders, cancer, autoimmune diseases and etc
165 The available treatment options for these metabolic disorders cannot reverse the disease in most i
166 s an ultra-rare, life-threatening, inherited metabolic disorder caused by deficiency of the mitochond
167 es showed that pseudoxanthoma elasticum is a metabolic disorder caused by reduced circulating levels
169 report five unrelated neonates with a lethal metabolic disorder characterized by cardiomyopathy, corn
170 irment in patients with diabetes mellitus, a metabolic disorder characterized by chronic hyperglycaem
171 Niemann-Pick Type C disease (NPC) is a rare metabolic disorder characterized by disruption of normal
172 cause hereditary tyrosinemia type I (HT1), a metabolic disorder characterized by elevated blood level
176 iderable value to the treatment algorithm of metabolic disorders characterized by dysregulated fatty
177 Ds) represent a group of monogenic inherited metabolic disorders characterized by the progressive acc
178 ion is observed in many neurodegenerative or metabolic disorders, congenital malformations are rare.
179 ia (MMA) is one of the most common inherited metabolic disorders, due to deficiency of the mitochondr
180 itive association between obesity-associated metabolic disorders (e.g., hyperlipidemia and diabetes)
181 male mice is vulnerable to a slowly emerging metabolic disorder following EHS that may harbinger long
183 at restore physiological feedback control in metabolic disorders foster advanced gene- and cell-based
184 implicated in the development of a range of metabolic disorders from insulin resistance (IR) to hepa
185 neutrophil dysfunction in the rare inherited metabolic disorder GSD-Ib without causing symptomatic hy
187 ion of acylcarnitines (ACs), often caused by metabolic disorders, has been associated with obesity, a
188 h the heterogeneous pathophysiology of human metabolic disorders, has limited the sustainability and
189 ding cancer, neurodegenerative diseases, and metabolic disorders, have been shown to be associated wi
190 rtant role in the development of obesity and metabolic disorders; however, it has not been fully unde
191 sing, metabolic switch implicated in various metabolic disorders; however, its role in inflammation i
192 ical molecular link between inflammation and metabolic disorders; however, the role of adipocyte IKKb
193 y treatment of HCV genotype-associated lipid metabolic disorders.IMPORTANCE Hepatic steatosis is a fr
201 oversupply of glucose-induced severe glucose metabolic disorders in MGs of lactating goats, shifting
205 from HFD males into normal zygotes generated metabolic disorders in the F1 offspring and altered gene
206 emale mice has the capacity to cause delayed metabolic disorders in the heart that could influence lo
209 s of selected amino acids (related to inborn metabolic disorders) in the unknown DBS was compared wit
210 in to control obesity and obesity-associated metabolic disorders including insulin resistance, fatty
213 risk in pregnancies complicated by maternal metabolic disorders, including diabetes and obesity.
214 stress, whereas superfluous lipolysis causes metabolic disorders, including dyslipidemia and hepatic
215 omeostasis and its alterations contribute to metabolic disorders, including fatty liver and diabetes.
216 n obese mice and reversed the progression of metabolic disorders, including hepatic steatosis, glucos
217 stemic inflammatory disease, associated with metabolic disorders, including high level of low-density
218 s largely unknown despite important roles in metabolic disorders, including obesity and nonalcoholic
219 pathogenic factor that characterizes various metabolic disorders, including obesity and type 2 diabet
220 sue compartments is tightly linked to severe metabolic disorders, including obesity, metabolic syndro
222 p duration has been associated with risk for metabolic disorders, including weight gain, diabetes, ob
223 eficiency diseases or obesity and associated metabolic disorders, increased risk of cardiovascular di
224 chanism by which hypercholesterolemia or any metabolic disorder increases cancer risk remains unknown
225 training reduced the severity of most of the metabolic disorders induced by a fructose-rich diet and
226 aerobic, strength, and combined training on metabolic disorders induced by a fructose-rich diet.
227 se tissue endocannabinoid levels and prevent metabolic disorders induced by a later high-fat diet (HF
228 results suggest a novel mechanism by which a metabolic disorder induces epigenetic changes to reduce
229 the treatment of conditions associated with metabolic disorders, inhibit KSHV lytic replication.
231 as a potential therapeutic strategy to treat metabolic disorders is highly sought after by the pharma
233 ension and related cardiovascular, renal and metabolic disorders is likely to become even more import
237 ormerly obese individuals are susceptible to metabolic disorders later in life, even after lifestyle
240 uided stratification of patients with common metabolic disorders, like diabetes and dyslipidemia, is
242 ncludes the sections: Hypertension, Imaging, Metabolic Disorders & Lipids, Neurovascular & Neurodegen
243 Part Two includes the sections: Imaging, Metabolic Disorders & Lipids, Rhythm Disorders, Statisti
244 Part Two includes the sections: Imaging, Metabolic Disorders & Lipids, Rhythm Disorders, Statisti
245 role of HCV in inflammation, immune evasion, metabolic disorders, liver pathogeneses, and efforts in
247 umption, which has also been associated with metabolic disorders, may also be linked to periodontal d
248 etroviral therapy frequently develop various metabolic disorders, neurocognitive abnormalities, and c
249 on of mTOR signalling has been implicated in metabolic disorders, neurodegeneration, cancer and agein
250 two essential organelles are associated with metabolic disorders, neurodegenerative diseases, and agi
252 novel therapeutic targets for patients with metabolic disorder or T2D who suffer from anxiety and de
255 uction of circulating SCFA may contribute to metabolic disorders promoting the progression of insulin
259 he association between sleep deprivation and metabolic disorders such as diabetes and obesity require
262 zing radiation increases the risk of chronic metabolic disorders such as insulin resistance and type
263 Moreover, we also discuss advances on how metabolic disorders such as metabolic syndrome and diabe
264 ubsequent metabolism have been implicated in metabolic disorders such as nonalcoholic fatty liver dis
267 ne with age and is implicated in age-related metabolic disorders such as obesity and type 2 diabetes
268 between intestinal microbial composition and metabolic disorders such as obesity and type 2 diabetes.
269 ute an appealing target for the treatment of metabolic disorders such as obesity, diabetes and hyperl
270 ontribute to neuronal function as well as to metabolic disorders such as type 2 diabetes mellitus, ob
272 cerbate the development and/or prevalence of metabolic disorders, such as obesity, is currently of gr
273 considered promising therapeutics for common metabolic disorders, such as obesity, liver steatosis, a
275 uman adipose tissue (hAT) is a key player in metabolic disorders, such as Type 2 Diabetes Mellitus (T
276 diseases, including a number of cancers and metabolic disorders, suggesting a role for NNMT as a pot
277 HCS cause holocarboxylase deficiency, a rare metabolic disorder that can be life-threatening if left
278 utations in the leptin gene (ob) result in a metabolic disorder that includes severe obesity(1), and
279 liver disease (NAFLD), a widespread hepatic metabolic disorder that is believed to be a risk factor
281 r, had preventive and therapeutic effects on metabolic disorders that were dependent on intestine HIF
282 ced gene expression patterns associated with metabolic disorders that were identified in blastocysts
283 f globally increasing risk factors including metabolic disorders, the incidence rates of HCC are stil
284 h the rising rates of obesity and associated metabolic disorders, there is a growing need for effecti
285 are linked to diseases spanning genetic and metabolic disorders to cancer and neurodegeneration.
286 ns, spanning from infections to cancer, from metabolic disorders to neurodegeneration and autoimmune
287 een shown to exhibit increased prevalence of metabolic disorders (type-2 diabetes, cardiovascular dis
291 pe and diabetic mice, with a known redox and metabolic disorder, we found that the cytoprotective nuc
292 ckout model demonstrates multiple immune and metabolic disorders, we investigated the role of each re
293 alkaloid Berberine (BRB), used for treating metabolic disorders, were studied on ex-vivo leukemic ce
295 sed dysregulated splicing events and hepatic metabolic disorders, which trigger endoplasmic reticulum
296 e that Alzheimer disease (AD) is a pervasive metabolic disorder with dysregulation in multiple bioche
298 iencies (MADDs) are a heterogeneous group of metabolic disorders with combined respiratory-chain defi